Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a significant drop in short interest in the month of June. As of June 30th, there was short interest totaling 6,105 shares, a drop of 70.1% from the June 15th total of 20,390 shares. Based on an average daily volume of 64,461 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC acquired a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma at the end of the most recent quarter. Institutional investors and hedge funds own 11.77% of the company’s stock.

Matinas Biopharma Stock Down 46.7%

Shares of MTNB stock traded down $0.35 during trading hours on Monday, hitting $0.40. 4,526,991 shares of the company’s stock were exchanged, compared to its average volume of 134,046. Matinas Biopharma has a fifty-two week low of $0.38 and a fifty-two week high of $3.09. The firm has a market cap of $2.58 million, a P/E ratio of -0.20 and a beta of 1.71. The firm has a 50 day moving average of $0.68 and a two-hundred day moving average of $0.63.

Matinas Biopharma (NYSEAMERICAN:MTNB) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.30) earnings per share (EPS) for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.